Evidence map›Paper›PMID 31188886›Full record

ArticlePloS one2019

MicroRNA expression profile in retina and choroid in oxygen-induced retinopathy model.

Michel Desjarlais, Jose Carlos Rivera, Isabelle Lahaie, Gaël Cagnone, Maëlle Wirt, Samy Omri, Sylvain Chemtob

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Serum miRNA modulations indicate changes in retinal morphology.Frontiers in molecular neuroscience · 2023
    Article
  11. MicroRNA Profiling in the Aqueous Humor of Keratoconus Eyes.Translational vision science & technology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. RNA therapeutics for retinal diseases.Expert opinion on biological therapy · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michel DesjarlaisDepartment of Ophthalmology, Maisonneuve-Rosemont Hospital Research Center, University of Montréal, Montréal, Québec, Canada.ORCID 0000-0002-5828-1760
Jose Carlos RiveraDepartment of Ophthalmology, Maisonneuve-Rosemont Hospital Research Center, University of Montréal, Montréal, Québec, Canada.
Isabelle LahaieDepartment of Ophthalmology, Maisonneuve-Rosemont Hospital Research Center, University of Montréal, Montréal, Québec, Canada.
Gaël CagnoneDepartments of Pediatrics, Ophthalmology and Pharmacology, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montréal, Québec, Canada.
Maëlle WirtDepartment of Ophthalmology, Maisonneuve-Rosemont Hospital Research Center, University of Montréal, Montréal, Québec, Canada.
Samy OmriDepartment of Ophthalmology, Maisonneuve-Rosemont Hospital Research Center, University of Montréal, Montréal, Québec, Canada.
Sylvain ChemtobDepartment of Ophthalmology, Maisonneuve-Rosemont Hospital Research Center, University of Montréal, Montréal, Québec, Canada.
Hôpital Maisonneuve-Rosemont · CACentre Hospitalier Universitaire Sainte-Justine · CA

Funding

CIHR
6 · The paper itself

Abstract

backgroundIschemic retinopathies (IRs) are leading causes of visual impairment. They are characterized by an initial phase of microvascular degeneration and a second phase of aberrant pre-retinal neovascularization (NV). microRNAs (miRNAs) regulate gene expression, and a number play a role in normal and pathological NV. But, post-transcriptional modulation of miRNAs in the eye during the development of IRs has not been systematically evaluated. AIMS &

methodsUsing Next Generation Sequencing (NGS) we profiled miRNA expression in the retina and choroid during vasodegenerative and NV phases of oxygen-induced retinopathy (OIR).

resultsApproximately 20% of total miRNAs exhibited altered expression (up- or down-regulation); 6% of miRNA were found highly expressed in retina and choroid of rats subjected to OIR. During OIR-induced vessel degeneration phase, miR-199a-3p, -199a-5p, -1b, -126a-3p displayed a robust decreased expression (> 85%) in the retina. While in the choroid, miR-152-3p, -142-3p, -148a-3p, -532-3p were upregulated (>200%) and miR-96-5p, -124-3p, -9a-3p, -190b-5p, -181a-1-3p, -9a-5p, -183-5p were downregulated (>70%) compared to controls. During peak pathological NV, miR-30a-5p, -30e-5p and 190b-5p were markedly reduced (>70%), and miR-30e-3p, miR-335, -30b-5p strongly augmented (by up to 300%) in the retina. Whereas in choroid, miR-let-7f-5p, miR-126a-5p and miR-101a-3p were downregulated by (>81%), and miR-125a-5p, let-7e-5p and let-7g-5p were upregulated by (>570%) during NV. Changes in miRNA observed using NGS were validated using qRT-PCR for the 24 most modulated miRNAs. In silico approach to predict miRNA target genes (using algorithms of miRSystem database) identified potential new target genes with pro-inflammatory, apoptotic and angiogenic properties.

conclusionThe present study is the first comprehensive description of retinal/choroidal miRNAs profiling in OIR (using NGS technology). Our results provide a valuable framework for the characterization and possible therapeutic potential of specific miRNAs involved in ocular IR-triggered inflammation, angiogenesis and degeneration.

Indexed as

AnimalsAnimals, NewbornChoroidDisease Models, AnimalEye AbnormalitiesEye ProteinsGene Expression RegulationHigh-Throughput Nucleotide SequencingHumansIschemiaMicroRNAsOxygenRatsRats, Sprague-DawleyRetinaRetinal NeovascularizationEye ProteinsMicroRNAsOxygen

Identifiers

PMID31188886
PMCPMC6561584
OpenAlexW2953327854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.